Pure curcumin increases the expression of SOCS1 and SOCS3 in myeloproliferative neoplasms through suppressing class I histone deacetylases

Carcinogenesis

Volumn 34, Issue 7, 2013, Pages 1442-1449

  Chen, Chi qi ^a   Yu, Kang ^a   Yan, Qing xian ^a   Xing, Chong yun ^a   YiChen, ^a   Yan, Zhuang ^a   Shi, Yi fen ^a   Zhao, Ke Wen ^b   Gao, Shen meng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 8; JANUS KINASE 2; SMALL INTERFERING RNA; STAT5 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRICHOSTATIN A;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; CLONOGENESIS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC TRANSCRIPTION; HEMATOPOIETIC STEM CELL; HISTONE ACETYLATION; HUMAN; MOUSE; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; THROMBOCYTOSIS;

ACETYLATION; BONE MARROW NEOPLASMS; CHROMATIN IMMUNOPRECIPITATION; CURCUMIN; ENZYME ACTIVATION; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; JANUS KINASE 2; K562 CELLS; MYELOPROLIFERATIVE DISORDERS; PRIMARY CELL CULTURE; PROMOTER REGIONS, GENETIC; REPRESSOR PROTEINS; RNA, SMALL INTERFERING; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 84880286355     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt070     Document Type: Article

References (46)

1. Greenhalgh, C.J. et al. (2001) Negative regulation of cytokine signaling. J. Leukoc. Biol., 70, 348-356.
2. Eyles, J.L. et al. (2002) Negative regulation of interleukin-12 signaling by suppressor of cytokine signaling-1. J. Biol. Chem., 277, 43735-43740.
3. Ungureanu, D. et al. (2002) Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1. Mol. Cell. Biol., 22, 3316-3326.
4. Sasaki, A. et al. (2000) CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2. J. Biol. Chem., 275, 29338-29347.
5. James, C. et al. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 434, 1144-1148.
6. Pardanani, A.D. et al. (2006) MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood, 108, 3472-3476.
7. Hookham, M.B. et al. (2007) The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. Blood, 109, 4924-4929.
8. Delcuve, G.P. et al. (2012) Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors. Clin. Epigenetics, 4, 5.
9. Senese, S. et al. (2007) Role for histone deacetylase 1 in human tumor cell proliferation. Mol. Cell. Biol., 27, 4784-4795.
10. Halkidou, K. et al. (2004) Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate, 59, 177-189.
11. Oehme, I. et al. (2009) Targeting of HDAC8 and investigational inhibitors in neuroblastoma. Expert Opin. Investig. Drugs, 18, 1605-1617.
12. Marks, P.A. (2010) The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin. Investig. Drugs, 19, 1049-1066.
13. Prince, H.M. et al. (2009) Clinical studies of histone deacetylase inhibitors. Clin. Cancer Res., 15, 3958-3969.
14. Myzak, M.C. et al. (2006) Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells. Carcinogenesis, 27, 811-819.
15. Thakur, V.S. et al. (2012) Green tea polyphenols causes cell cycle arrest and apoptosis in prostate cancer cells by suppressing class I histone deacetylases. Carcinogenesis, 33, 377-384.
16. Kuttan, R. et al. (1985) Potential anticancer activity of turmeric (Curcuma longa). Cancer Lett., 29, 197-202.
17. Tan, T.W. et al. (2006) Curcumin-induced cell cycle arrest and apoptosis in human acute promyelocytic leukemia HL-60 cells via MMP changes and caspase-3 activation. Anticancer Res., 26, 4361-4371.
18. Glienke, W. et al. (2009) Wilms' tumour gene 1 (WT1) as a target in curcumin treatment of pancreatic cancer cells. Eur. J. Cancer, 45, 874-880.
19. Bharti, A.C. et al. (2003) Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood, 101, 1053-1062.
20. Mackenzie, G.G. et al. (2008) Curcumin induces cell-arrest and apoptosis in association with the inhibition of constitutively active NF-kappaB and STAT3 pathways in Hodgkin's lymphoma cells. Int. J. Cancer, 123, 56-65.
21. Blasius, R. et al. (2006) Curcumin regulates signal transducer and activator of transcription (STAT) expression in K562 cells. Biochem. Pharmacol., 72, 1547-1554.
22. Fu, S. et al. (2010) Development of curcumin as an epigenetic agent. Cancer, 116, 4670-4676.
23. Parashar, G. et al. (2012) Curcumin causes promoter hypomethylation and increased expression of FANCF gene in SiHa cell line. Mol. Cell. Biochem., 365, 29-35.
24. Liu, H.L. et al. (2005) Curcumin, a potent anti-tumor reagent, is a novel histone deacetylase inhibitor regulating B-NHL cell line Raji proliferation. Acta Pharmacol. Sin., 26, 603-609.
25. Walz, C. et al. (2012) Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice. Blood, 119, 3550-3560.
26. Ram, P.A. et al. (1999) SOCS/CIS protein inhibition of growth hormonestimulated STAT5 signaling by multiple mechanisms. J. Biol. Chem., 274, 35553-35561.
27. Lee, S.J. et al. (2011) Curcumin-induced HDAC inhibition and attenuation of medulloblastoma growth in vitro and in vivo. BMC Cancer, 11, 144.
28. Yang, C.L. et al. (2012) Curcumin blocks small cell lung cancer cells migration, invasion, angiogenesis, cell cycle and neoplasia through Janus kinase-STAT3 signalling pathway. PLoS ONE, 7, e37960.
29. Seo, J.H. et al. (2010) Lysophosphatidic acid induces STAT3 phosphorylation and ovarian cancer cell motility: their inhibition by curcumin. Cancer Lett., 288, 50-56.
30. Rajasingh, J. et al. (2006) Curcumin induces growth-arrest and apoptosis in association with the inhibition of constitutively active JAK-STAT pathway in T cell leukemia. Biochem. Biophys. Res. Commun., 340, 359-368.
31. Guerini, V. et al. (2008) The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia, 22, 740-747.
32. Quintas-Cardama, A. et al.(2009) Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood, 113, 1619-1630.
33. Wolanin, K. et al. (2006) Curcumin affects components of the chromosomal passenger complex and induces mitotic catastrophe in apoptosis-resistant Bcr-Abl-expressing cells. Mol. Cancer Res., 4, 457-469.
34. Capello, D. et al. (2008) Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders. Br. J. Haematol., 141, 504-511.
35. Fourouclas, N. et al. (2008) Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders. Haematologica, 93, 1635-1644.
36. Xiong, H. et al. (2012) Trichostatin A, a histone deacetylase inhibitor, suppresses JAK2/STAT3 signaling via inducing the promoter-associated histone acetylation of SOCS1 and SOCS3 in human colorectal cancer cells. Mol. Carcinog., 51, 174-184.
37. Akada, H. et al. (2012) Efficacy of vorinostat in a murine model of polycythemia vera. Blood, 119, 3779-3789.
38. Yan, G. et al. (2012) Curcumin enhances the anticancer effects of trichostatin a in breast cancer cells. Mol. Carcinog., doi: 10.1002/mc.21875.
39. Giommarelli, C. et al. (2010) The enhancement of antiproliferative and proapoptotic activity of HDAC inhibitors by curcumin is mediated by Hsp90 inhibition. Cell. Mol. Life Sci., 67, 995-1004.
40. Bora-Tatar, G. et al. (2009) Molecular modifications on carboxylic acid derivatives as potent histone deacetylase inhibitors: activity and docking studies. Bioorg. Med. Chem., 17, 5219-5228.
41. Van den Wyngaert, I. et al. (2000) Cloning and characterization of human histone deacetylase 8. FEBS Lett., 478, 77-83.
42. Oehme, I. et al. (2009) Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin. Cancer Res., 15, 91-99.
43. Yan, W. et al. (2013) Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8. Oncogene, 32, 599-609.
44. Vannini, A. et al. (2004) Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc. Natl Acad. Sci. U.S.A., 101, 15064-15069.
45. Balasubramanian, S. et al. (2008) A novel histone deacetylase 8 (HDAC8)- specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia, 22, 1026-1034.
46. Xiong, S.D. et al. (2009) Ribosome-inactivating proteins isolated from dietary bitter melon induce apoptosis and inhibit histone deacetylase-1 selectively in premalignant and malignant prostate cancer cells. Int. J. Cancer, 125, 774-782.